Highlights Catalent, Inc.

Equities

CTLT

US1488061029

Market Closed - Nyse Other stock markets 04:00:01 2024-07-09 pm EDT			5-day change	1st Jan Change
57.3 ^USD	+0.33%		+1.96%	+27.53%

Jun. 28	Barclays Raises Catalent's Price Target to $63 From $47, Maintains Equalweight Rating	MT
Jun. 27	Barclays Adjusts Catalent Price Target to $63 From $47	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Catalent Shareholders Approve Deal With Novo Holdings	May. 29	MT
Catalent stockholders approve deal with Novo Holdings	May. 29	RE
Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal	May. 14	MT
Novo Nordisk Plans First Bond Sale in Two Years	May. 14	MT
MOVES -Lazard hires veteran healthcare dealmaker Colocci as vice chairman	May. 09	RE
Earnings Flash (CTLT) CATALENT Posts Q3 Revenue $1.07B	May. 08	MT
Catalent, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 08	CI
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer	May. 08	CI
Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition	May. 03	MT
Catalent, Novo Nordisk Antitrust Review Extended by FTC	May. 03	MT
FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal	May. 03	DJ
US FTC seeks more information on Novo Nordisk parent-Catalent deal	May. 03	RE
FTC seeks more information on Novo Holdings-Catalent deal	May. 03	RE
Obesity drugmaker Novo Nordisk raises outlook, Q1 profit beats forecast	May. 02	RE
Obesity drugmaker Novo Nordisk's Q1 profit beats forecast	May. 02	RE
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
Novo Nordisk Parent Resubmits US Antirust Application for Catalent Acquisition	Apr. 08	MT
Novo Nordisk parent refiles US application on Catalent deal	Apr. 08	RE
Novo Nordisk owner refiles U.S. application for approval of Catalent deal	Apr. 08	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Catalent, Inc.

Equities

CTLT

US1488061029

Highlights

Filters